✅ No sanctions, screening, insolvency or control red flags found in the public sources we cover. (Absence of a flag is not a guarantee — see methodology.)
ILTOO PHARMA
5710 · RC 539438499 · Active since 2012
Overview
ILTOO PHARMA is a 5710 registered , France, since 2012. The company operates in the 7211 sector. With reported revenue of 1.7M EUR in 2016. Its TraceComp score of 66 (B) indicates moderate risk with some areas to watch. With 14 years of operations, the company has an established track record in its market.
Company Information
- Registration Number
- 539438499
- Legal Form
- 5710
- Registered
- 2012-01-23
Financial Profile
Latest filed accounts: FY 2016 · most recent available in public filings
Multi-year financials & ratios
1 year of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Officers & Management
4 officers/directors on file — names, roles, appointment & resignation dates.
| Name | Role | Status |
|---|---|---|
| PIERRE Belichard | role 65 | Current |
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Research Output
Active research organization. 29 publications · 5,726 citations · h-index 18 in the global scholarly record (OpenAlex — 82.9M papers). Top fields by publication volume: Medicine (44%) · Immunology and Microbiology (28%) · Biochemistry, Genetics and Molecular Biology (16%).
See full research profile — top researchers & publications →
Source: OpenAlex (CC0). Objective publication & citation counts.
EU Funding
EU-funded innovation. Participated in 3 EU research projects, receiving €1,515,688 in EU contributions (CORDIS — Horizon Europe / Horizon 2020).
Source: CORDIS (EU Open Data, CC-BY). Cumulative EC contribution across the company’s projects.
Patent Portfolio
Active patent holder. 4 patents · 4 active · 4 granted in the USPTO/EPO record.
See full patent portfolio — most-cited inventions & inventors →
Source: USPTO / EPO open patent data. Objective bibliographic counts.
Risk Signals
No adverse legal events have been recorded for this company.
- Net loss reported in FY 2016
- Altman Z-Score in the distress zone — elevated insolvency risk on the model
Data Sources & Freshness
Data sourced from: bulk register.